Valuation: CROSSJECT

Market Cap 82.54M 95.06M 76.96M 70.69M 134M 9.04B 135M 907M 355M 4.52B 357M 349M 14.98B P/E 2026 *
3.7x
P/E 2027 * 2.92x
Enterprise Value 64.64M 74.44M 60.27M 55.36M 105M 7.08B 106M 711M 278M 3.54B 280M 273M 11.73B EV / Sales 2026 *
1.06x
EV / Sales 2027 * 0.84x
Free-Float
90.34%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 07/08/2001
Director of Finance/CFO - 24/03/2026
Corporate Officer/Principal - 19/08/2024
Director TitleAgeSince
Chairman 67 25/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+3.09%+6.80%-32.81%-52.26% 104M
-1.21%+1.24%+87.84%+12.81% 80.25M
Average +0.94%+7.79%+27.51%-19.72% 92.37M
Weighted average by Cap. +1.22%+8.28%+19.60%-23.99%

Financials

2026 *2027 *
Net sales 60.8M 70.02M 56.69M 52.08M 98.49M 6.66B 99.57M 668M 261M 3.33B 263M 257M 11.03B 42.3M 48.72M 39.44M 36.23M 68.52M 4.63B 69.27M 465M 182M 2.32B 183M 179M 7.68B
Net income 28.3M 32.59M 26.39M 24.24M 45.84M 3.1B 46.35M 311M 122M 1.55B 122M 120M 5.14B 7.75M 8.93M 7.23M 6.64M 12.55M 849M 12.69M 85.19M 33.3M 424M 33.52M 32.78M 1.41B
Net Debt -17.9M -20.61M -16.69M -15.33M -29M -1.96B -29.31M -197M -76.92M -980M -77.42M -75.72M -3.25B -47M -54.13M -43.82M -40.26M -76.14M -5.15B -76.97M -517M -202M -2.57B -203M -199M -8.53B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-